1
|
Rhouma FB, Messai H, Hsouna S, Halim NB, Cherif W, Fadhel SB, Tiar A, Nagara M, Azzouz H, Sfar MT, Dridi MFB, Tebib N, Ayadi A, Abdelhak S, Kefi R. History of settlement of villages from Central Tunisia by studying families sharing a common founder Glycogenosis type III mutation. Mitochondrial DNA A DNA Mapp Seq Anal 2015; 27:3194-8. [PMID: 26704523 DOI: 10.3109/19401736.2015.1007331] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022]
Abstract
Glycogen storage disease type III (GSD III; Cori disease; Forbes disease) is an autosomal recessive inherited metabolic disorder resulting from deficient glycogen debrancher enzyme activity in liver and muscle. In this study, we focused on a single AGL gene mutation p.W1327X in 16 Tunisian patients from rural area surrounding the region of Mahdia in Central Tunisia. This constitutes the largest pool of patients with this mutation ever described. This study was performed to trace the history of the patients' ancestries in a single region. After extraction of genomic DNA, exon 31 of AGL gene was sequenced. The patients were investigated for the hypervariable segment 1 of mitochondrial DNA and 17 Y-STR markers. We found that the p.W1327X mutation was a founder mutation in Tunisia Analysis of maternal lineages shows an admixture of autochthonous North African, sub-Saharan and a predominance of Eurasian haplogroups. Heterogeneity of maternal haplogroups indicates an ancient settlement. However, paternal gene flow was highly homogeneous and originates from the Near East. We hypothesize that the p.W1327X mutation was introduced into the Tunisian population probably by a recent migration event; then the mutation was fixed in a small region due to the high rate of consanguineous marriages and genetic drift. The screening for this mutation should be performed in priority for GSD III molecular diagnosis, for patients from the region of Mahdia and those from regions sharing the same settlement history.
Collapse
Affiliation(s)
- Faten Ben Rhouma
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Habib Messai
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Sana Hsouna
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Nizar Ben Halim
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Wafa Cherif
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Sihem Ben Fadhel
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Afaf Tiar
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Majdi Nagara
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Hatem Azzouz
- c Département de Pédiatrie , Hôpital La Rabta de Tunis, Unité des maladies métaboliques héréditaires , Tunis , Tunisia .,d Faculté de Médecine de Tunis , Tunis , Tunisia , and
| | | | - Marie-Françoise Ben Dridi
- c Département de Pédiatrie , Hôpital La Rabta de Tunis, Unité des maladies métaboliques héréditaires , Tunis , Tunisia .,d Faculté de Médecine de Tunis , Tunis , Tunisia , and
| | - Neji Tebib
- c Département de Pédiatrie , Hôpital La Rabta de Tunis, Unité des maladies métaboliques héréditaires , Tunis , Tunisia .,d Faculté de Médecine de Tunis , Tunis , Tunisia , and
| | - Abdelkarim Ayadi
- e Département de Pédiatrie , Hôpital Tahar Sfar , Mahdia , Tunisia
| | - Sonia Abdelhak
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| | - Rym Kefi
- a Institut Pasteur de Tunis, Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05 , Tunis , Tunisia .,b Université Tunis El Manar , Tunis , Tunisia
| |
Collapse
|
2
|
Ben Rhouma F, Azzouz H, Petit FM, Khelifa MB, Chehida AB, Nasrallah F, Parisot F, Lasram K, Kefi R, Bouyacoub Y, Romdhane L, Baussan C, Kaabachi N, Ben Dridi MF, Tebib N, Abdelhak S. Molecular and biochemical characterization of a novel intronic single point mutation in a Tunisian family with glycogen storage disease type III. Mol Biol Rep 2013; 40:4197-202. [PMID: 23649758 DOI: 10.1007/s11033-013-2500-z] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/13/2013] [Accepted: 04/27/2013] [Indexed: 10/26/2022]
Abstract
Genetic deficiency of the glycogen debranching enzyme causes glycogen storage disease type III, an autosomal recessive inherited disorder. The gene encoding this enzyme is designated as AGL gene. The disease is characterized by fasting hypoglycemia, hepatomegaly, growth retardation, progressive myopathy and cardiomyopathy. In the present study, we present clinical features and molecular characterization of two consanguineous Tunisian siblings suffering from Glycogen storage disease type III. The full coding exons of the AGL gene and their corresponding exon-intron boundaries were amplified for the patients and their parents. Gene sequencing identified a novel single point mutation at the conserved polypyrimidine tract of intron 21 in a homozygous state (IVS21-8A>G). This variant cosegregated with the disease and was absent in 102 control chromosomes. In silico analysis using online resources showed a decreased score of the acceptor splice site of intron 21. RT-PCR analysis of the AGL splicing pattern revealed a 7 bp sequence insertion between exon 21 and exon 22 due to the creation of a new 3' splice site. The predicted mutant enzyme was truncated by the loss of 637 carboxyl-terminal amino acids as a result of premature termination. This novel mutation is the first mutation identified in the region of Bizerte and the tenth AGL mutation identified in Tunisia. Screening for this mutation can improve the genetic counseling and prenatal diagnosis of GSD III.
Collapse
Affiliation(s)
- Faten Ben Rhouma
- Laboratoire de Genomique Biomedicale et Oncogenetique LR11IPT05, Institut Pasteur de Tunis, 1002, Tunis, Tunisia
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
3
|
Turkia HB, Gonzalez DE, Barton NW, Zimran A, Kabra M, Lukina EA, Giraldo P, Kisinovsky I, Bavdekar A, Dridi MFB, Gupta N, Kishnani PS, Sureshkumar E, Wang N, Crombez E, Bhirangi K, Mehta A. Velaglucerase alfa enzyme replacement therapy compared with imiglucerase in patients with Gaucher disease. Am J Hematol 2013; 88:179-84. [PMID: 23400823 DOI: 10.1002/ajh.23382] [Citation(s) in RCA: 51] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Revised: 11/23/2012] [Accepted: 12/12/2012] [Indexed: 11/11/2022]
Abstract
Enzyme replacement therapy for Gaucher disease (GD) has been available since 1991. This study compared the efficacy and safety of velaglucerase alfa with imiglucerase, the previous standard of care. A 9-month, global, randomized, double-blind, non-inferiority study compared velaglucerase alfa with imiglucerase (60 U/kg every other week) in treatment-naïve patients aged 3-73 years with anemia and either thrombocytopenia or organomegaly. The primary endpoint was the difference between groups in mean change from baseline to 9 months in hemoglobin concentration. 35 patients were randomized: 34 received study drug (intent-to-treat: 17 per arm), 20 were splenectomized. Baseline characteristics were similar in the two groups. The per-protocol population included 15 patients per arm. The mean treatment difference for hemoglobin concentration from baseline to 9 months (velaglucerase alfa minus imiglucerase) was 0.14 and 0.16 g/dL in the intent-to-treat and per-protocol populations, respectively. The lower bound of the 97.5% one-sided confidence interval in both populations lay within the pre-defined non-inferiority margin of -1.0 g/dL, confirming that velaglucerase alfa is non-inferior to imiglucerase. There were no statistically significant differences in the secondary endpoints. Most adverse events were mild to moderate. No patient receiving velaglucerase alfa developed antibodies to either drug, whereas four patients (23.5%) receiving imiglucerase developed IgG antibodies to imiglucerase, which were cross-reactive with velaglucerase alfa in one patient. This study demonstrates the efficacy and safety of velaglucerase alfa compared with imiglucerase in adult and pediatric patients with GD clinically characterized as Type 1. Differences in immunogenicity were also observed.
Collapse
Affiliation(s)
| | | | | | - Ari Zimran
- Shaare Zedek Medical Center and Hebrew University-Hadassah Medical School; Jerusalem; Israel
| | | | | | - Pilar Giraldo
- Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) and Hospital Universitario Miguel Servet; Zaragoza; Spain
| | | | | | | | - Neerja Gupta
- All India Institute of Medical Sciences; New Delhi; India
| | | | | | - Nan Wang
- Shire Human Genetic Therapies, Inc.; Lexington; Massachusetts
| | - Eric Crombez
- Shire Human Genetic Therapies, Inc.; Lexington; Massachusetts
| | - Kiran Bhirangi
- Shire Human Genetic Therapies, Inc.; Lexington; Massachusetts
| | - Atul Mehta
- Royal Free Hospital, University College London School of Medicine; London; United Kingdom
| |
Collapse
|
4
|
Gonzalez DE, Turkia HB, Lukina EA, Kisinovsky I, Dridi MFB, Elstein D, Zahrieh D, Crombez E, Bhirangi K, Barton NW, Zimran A. Enzyme replacement therapy with velaglucerase alfa in Gaucher disease: Results from a randomized, double-blind, multinational, Phase 3 study. Am J Hematol 2013; 88:166-71. [PMID: 23386328 DOI: 10.1002/ajh.23381] [Citation(s) in RCA: 55] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/30/2012] [Revised: 11/23/2012] [Accepted: 12/12/2012] [Indexed: 12/21/2022]
Abstract
Type 1 Gaucher disease (GD1), resulting from glucocerebrosidase deficiency, leads to splenomegaly, hepatomegaly, anemia, thrombocytopenia, and bone involvement. Current standard treatment is enzyme replacement therapy. Velaglucerase alfa is an enzyme replacement product for GD1, with the same amino acid sequence as naturally occurring human glucocerebrosidase. This multinational, Phase 3 trial evaluated the efficacy and safety of two doses of velaglucerase alfa in 25 treatment-naïve, anemic patients with GD1 (4-62 years of age), randomized to intravenous velaglucerase alfa 60 U/kg (n=12) or 45 U/kg body weight (n=13) every other week for 12 months. The primary endpoint was change from baseline in hemoglobin concentration in the 60 U/kg arm. At 12 months, mean hemoglobin concentrations increased from baseline [60 U/kg: +23.3%; +2.43 g/dL (P<0.001); 45 U/kg: +23.8%; +2.44 g/dL (P<0.001)], as did mean platelet counts [60 U/kg: +65.9%; +50.9 × 10(9) /L (P=0.002); 45 U/kg: +66.4%; +40.9 × 10(9) /L(P=0.01)]. Mean splenic volume decreased from baseline [60 U/kg: -50.4%, from 14.0 to 5.8 multiples of normal (MN) (P=0.003); 45 U/kg: -39.9%, from 14.5 to 9.5 MN (P=0.009)]. No drug-related serious adverse events or withdrawals were observed. One patient developed antibodies. Velaglucerase alfa was generally well tolerated and effective for adults and children with GD1 in this study. All disease-specific parameters measured demonstrated clinically meaningful improvements after 12 months.
Collapse
Affiliation(s)
| | | | | | | | | | - Deborah Elstein
- Shaare Zedek Medical Center and Hebrew University-Hadassah Medical School; Jerusalem; Israel
| | - David Zahrieh
- Shire Human Genetic Therapies, Inc.; Lexington; Massachusetts
| | - Eric Crombez
- Shire Human Genetic Therapies, Inc.; Lexington; Massachusetts
| | - Kiran Bhirangi
- Shire Human Genetic Therapies, Inc.; Lexington; Massachusetts
| | | | - Ari Zimran
- Shaare Zedek Medical Center and Hebrew University-Hadassah Medical School; Jerusalem; Israel
| |
Collapse
|
5
|
Ben Halim N, Ben Alaya Bouafif N, Romdhane L, Kefi Ben Atig R, Chouchane I, Bouyacoub Y, Arfa I, Cherif W, Nouira S, Talmoudi F, Lasram K, Hsouna S, Ghazouani W, Azaiez H, El Matri L, Abid A, Tebib N, Ben Dridi MF, Kachboura S, Amouri A, Mokni M, Ben Arab S, Dellagi K, Abdelhak S. Consanguinity, endogamy, and genetic disorders in Tunisia. J Community Genet 2012. [PMID: 23208456 DOI: 10.1007/s12687-012-0128-7] [Citation(s) in RCA: 62] [Impact Index Per Article: 5.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/29/2023] Open
Affiliation(s)
- Nizar Ben Halim
- Laboratory of Biomedical Genomics and Oncogenetics, Pasteur Institute of Tunis, BP 74, 13 Place Pasteur, Tunis, Le Belvédère, 1002, Tunisia,
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|